<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The classical clinical picture of the <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) is characterized by venous or arterial thromboses, fetal losses and <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo>, in the presence of <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> (aPL), namely <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi>, anticardiolipin antibodies or antibodies directed to various proteins, mainly Î²2 glycoprotein I, or <z:hpo ids='HP_0000001'>all</z:hpo> three </plain></SENT>
<SENT sid="1" pm="."><plain>Apart from being "primary" (without any discernable underlying systemic <z:hpo ids='HP_0002960'>autoimmune disease</z:hpo>), or associated to another disease (usually to <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo>), it may also occur rapidly over days or weeks when it has been termed "catastrophic" APS </plain></SENT>
<SENT sid="2" pm="."><plain>Therapy should not primarily be directed at effectively reducing the aPL levels and the use of immunotherapy (including high dose steroid administration, immunosuppression or plasma exchange) is generally not indicated, unless in the catastrophic APS </plain></SENT>
<SENT sid="3" pm="."><plain>Treatment of APS patients should be based on the use of antiaggregant and <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> therapy </plain></SENT>
</text></document>